NATHANIEL BROOKS HORWITZ
Founder at Avilar Therapeutics, Inc.
NATHANIEL BROOKS HORWITZ active positions
| Companies | Position | Start | End |
|---|---|---|---|
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Private Equity Analyst | 2020-11-30 | - |
GentiBio, Inc.
 GentiBio, Inc. BiotechnologyHealth Technology GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA. | Director/Board Member | 2019-12-31 | - |
| Founder | 2019-12-31 | - | |
Avilar Therapeutics, Inc.
 Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Founder | 2018-12-31 | - |
Superluminal Medicines Inc
 Superluminal Medicines Inc BiotechnologyHealth Technology Superluminal Medicines Inc is a generative biological and chemical company. The company is based in Boston, MA. The CEO of the company is Cony D'Cruz. | Director/Board Member | - | - |
Career history of NATHANIEL BROOKS HORWITZ
Former positions of NATHANIEL BROOKS HORWITZ
| Companies | Position | Start | End |
|---|---|---|---|
Nivien Therapeutics Co.
 Nivien Therapeutics Co. Miscellaneous Commercial ServicesCommercial Services Nivien Therapeutics Co. is an American biotechnology company that operates in the field of biotechnology. The private company was founded by Nathaniel Brooks Horwitz. | Chief Executive Officer | 2015-12-31 | 2018-12-30 |
| Founder | 2015-12-31 | 2018-12-30 | |
New Equilibrium Biosciences, Inc.
 New Equilibrium Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services New Equilibrium Biosciences, Inc. operates as a biotechnology company. The company is headquartered in Boston, MA. | Director/Board Member | 2021-02-28 | - |
Training of NATHANIEL BROOKS HORWITZ
| Harvard University | Undergraduate Degree |
Statistics
International
| United States | 8 |
Operational
| Founder | 3 |
| Director/Board Member | 3 |
| Private Equity Analyst | 1 |
Sectoral
| Commercial Services | 4 |
| Health Technology | 3 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 6 |
|---|---|
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Finance |
New Equilibrium Biosciences, Inc.
New Equilibrium Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services New Equilibrium Biosciences, Inc. operates as a biotechnology company. The company is headquartered in Boston, MA. | Commercial Services |
GentiBio, Inc.
GentiBio, Inc. BiotechnologyHealth Technology GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA. | Health Technology |
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Commercial Services |
Nivien Therapeutics Co.
Nivien Therapeutics Co. Miscellaneous Commercial ServicesCommercial Services Nivien Therapeutics Co. is an American biotechnology company that operates in the field of biotechnology. The private company was founded by Nathaniel Brooks Horwitz. | Commercial Services |
Superluminal Medicines Inc
Superluminal Medicines Inc BiotechnologyHealth Technology Superluminal Medicines Inc is a generative biological and chemical company. The company is based in Boston, MA. The CEO of the company is Cony D'Cruz. | Health Technology |
